论文部分内容阅读
目的:掌握淄博市流行的HIV-1感染者基因亚型，了解淄博市耐药病毒株的传播水平，为艾滋病预防控制工作提供依据。方法:收集本地区HIV-1感染者的血浆标本，采用RT-PCR和巢式PCR法扩增env基因区和pol基因区，经DNA纯化及测序后，利用HIV database数据库和Mega 6.0软件分析并确定HIV病毒亚型，使用美国斯坦福大学HIV耐药数据库进行耐药分析。结果:共采集HIV-1感染者血浆标本72份，通过分析发现本地区共存在4种基因亚型，其中CRF01_AE重组亚型占47.22%，CRF07_BC重组亚型占31.94%，B亚型占12.50%，B/C重组亚型占8.33%。耐药分析发现本地区未治疗患者的原发耐药率为6.98%。M184V是核苷类逆转录酶区的主要耐药突变位点，V179D为非核苷类逆转录酶区的主要耐药突变位点。结论:淄博市HIV-1感染者的基因亚型存在多样性，耐药的发生率较高，属于中度流行。亟需加强对HIV-1毒株重组亚型变异监测及耐药监测，从而预防原发性耐药和耐药毒株的传播。“,”Objective:To understand the genetic subtypes of HIV-1 infected patients and the circulation level of drug-resistant HIV strains in Zibo city, so as to provide evidences for AIDS prevention and control.Methods:Plasma samples were collected from HIV-1 infected patients in the city, and the env gene region and pol gene region were amplified using RT-PCR and nested PCR. After DNA purification and sequencing, the genetic subtypes of HIV were analyzed and determined using HIV database and Mega 6.0 software, and drug resistance analysis was performed using the HIV drug resistance database of Stanford University.Results:A total of 72 plasma specimens from HIV-1 infected patients were collected. The analysis results indicated that 4 genetic subtypes existed in the city. The CRF01_AE recombinant subtype accounted for 47.22%, CRF07_BC recombinant subtype accounted for 31.94%, B subtype accounted for 12.50%, and B/C recombinant subtype accounted for 8.33%. The drug resistance analysis found that the primary drug resistance rate of untreated patients in the region was 6.98%. M184V was the main resistance mutation site in the nucleoside reverse transcriptase region, and V179D was the main resistance mutation site in the non-nucleoside reverse transcriptase region.Conclusions:The genetic subtypes among HIV-1 infected patients were diverse in Zibo city, and the incidence of drug resistance was relatively high, reaching the lvevel of moderate epidemic. There is an urgent need to strengthen the surveillance of recombinant subtype mutations and drug resistance of HIV-1 strains to prevent the spread of primary drug resistance and drug-resistant strains.